New hope for transplant patients: shorter drug course may beat stubborn virus
NCT ID NCT07511127
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the best length of treatment with the drug maribavir for a hard-to-treat CMV infection that can happen after a stem cell transplant. About 218 adults who have already had a transplant and have this infection will be randomly assigned to different treatment durations. The goal is to see which approach best prevents the infection from coming back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital, Shanghai JiaoTong University School of Medicine
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Frailty check may steer safer cancer care for seniors
- Could gratitude exercises aid blood cancer recovery?
- Can a new tracer light up cancer growth?
- Could a walk a day keep brain fog away after a stem cell transplant?
- Could End-of-Life care for blood cancer patients be done at home?